{"product_id":"002880sz-business-model-canvas","title":"Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ): Canvas Business Model","description":"\u003cp\u003eDelve into the dynamic world of Shenzhen Weiguang Biological Products Co., Ltd., a frontrunner in the biotech industry. With its innovative approach and robust business model canvas, this company not only excels in producing high-quality biological products but also champions research and development. Discover the key elements that drive its success, from strategic partnerships to diverse revenue streams, and learn how this company navigates the complex landscape of health solutions.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen Weiguang Biological Products Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eShenzhen Weiguang Biological Products Co., Ltd. engages in various partnerships critical for its operational success and market positioning. The company’s collaboration with external entities boosts its capabilities, enhances its product offerings, and mitigates potential risks.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Health Departments\u003c\/h3\u003e\n\n\u003cp\u003ePartnerships with government health departments are vital for regulatory compliance and product approvals. For instance, Weiguang has collaborated with the \u003cstrong\u003eNational Health Commission of China\u003c\/strong\u003e, facilitating access to essential health data and regulatory support. In 2022, the company successfully registered \u003cstrong\u003e15 new biological products\u003c\/strong\u003e through this partnership.\u003c\/p\u003e\n\n\u003cp\u003eThe partnership extends to public health initiatives where Weiguang contributes to vaccination drives and health awareness programs, aligning with government objectives and enhancing its corporate reputation.\u003c\/p\u003e\n\n\u003ch3\u003eMedical Research Institutions\u003c\/h3\u003e\n\n\u003cp\u003eWeiguang maintains strategic affiliations with prominent medical research institutions such as the \u003cstrong\u003eShenzhen University Medical School\u003c\/strong\u003e and the \u003cstrong\u003eChinese Academy of Medical Sciences\u003c\/strong\u003e. These collaborations enable joint research and development (R\u0026amp;D) projects, leading to innovations in biological products.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eIn 2022, joint research projects generated over \u003cstrong\u003e$10 million\u003c\/strong\u003e in funding, showcasing the financial impact of these partnerships.\u003c\/li\u003e\n\u003cli\u003ePublication of several peer-reviewed papers in respected journals, enhancing Weiguang’s credibility and visibility within the industry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eSuppliers for Raw Biological Materials\u003c\/h3\u003e\n\n\u003cp\u003eWeiguang’s supply chain relies heavily on partnerships with suppliers of raw biological materials. The company sources materials from both local and international suppliers, ensuring quality and consistency in production. Key suppliers include:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBayer AG\u003c\/strong\u003e - supplying critical components for vaccine production.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThermo Fisher Scientific\u003c\/strong\u003e - providing reagents and raw materials essential for R\u0026amp;D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn 2023, the cost of raw materials accounted for approximately \u003cstrong\u003e40% of total production expenses\u003c\/strong\u003e, reflecting the significance of these partnerships in maintaining operational efficiency and cost management.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplier\u003c\/th\u003e\n\u003cth\u003eCountry\u003c\/th\u003e\n\u003cth\u003eAnnual Supply Value (USD)\u003c\/th\u003e\n\u003cth\u003eSupplied Products\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBayer AG\u003c\/td\u003e\n\u003ctd\u003eGermany\u003c\/td\u003e\n\u003ctd\u003e5,000,000\u003c\/td\u003e\n\u003ctd\u003eVaccine components\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThermo Fisher Scientific\u003c\/td\u003e\n\u003ctd\u003eUSA\u003c\/td\u003e\n\u003ctd\u003e3,500,000\u003c\/td\u003e\n\u003ctd\u003eReagents, raw materials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina National Pharmaceutical Group\u003c\/td\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003e2,000,000\u003c\/td\u003e\n\u003ctd\u003eBiological raw materials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese partnerships not only provide essential materials but also offer cost advantages through negotiated contracts, which help Weiguang maintain competitive pricing in the market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen Weiguang Biological Products Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eShenzhen Weiguang Biological Products Co., Ltd.\u003c\/strong\u003e is a prominent player in the field of biological products, specializing in the production of innovative healthcare solutions. The company's key activities are pivotal in sustaining its competitive advantage and ensuring the delivery of its value proposition.\u003c\/p\u003e\n\n\u003ch3\u003eProduction of biological products\u003c\/h3\u003e\n\n\u003cp\u003eThe production process is central to Weiguang's operations, emphasizing efficiency and scalability. In 2022, the company reported an annual production capacity of over \u003cstrong\u003e10 million units\u003c\/strong\u003e of biological products, encompassing vaccines, diagnostic reagents, and other health-related items. The production facilities are equipped with advanced biotechnological machinery to maintain high standards of safety and efficacy.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and development\u003c\/h3\u003e\n\n\u003cp\u003eResearch and development (R\u0026amp;D) drive innovation at Weiguang. In 2022, the company invested approximately \u003cstrong\u003e15% of its revenue\u003c\/strong\u003e into R\u0026amp;D, amounting to around \u003cstrong\u003e¥150 million\u003c\/strong\u003e (approximately \u003cstrong\u003e$22 million\u003c\/strong\u003e). This investment has led to the development of several patented technologies and formulations, enhancing their portfolio with products that meet rising health demands.\u003c\/p\u003e\n\n\u003ch3\u003eQuality control and assurance\u003c\/h3\u003e\n\n\u003cp\u003eQuality control is paramount in ensuring the safety and effectiveness of biological products. Weiguang implements rigorous quality assurance protocols in compliance with both domestic and international standards. The company conducts over \u003cstrong\u003e2000 quality tests\u003c\/strong\u003e annually, ensuring that each batch of products meets the required specifications. In 2022, the company maintained a quality pass rate of \u003cstrong\u003e99.5%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Activity\u003c\/th\u003e\n        \u003cth\u003eMetrics\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduction Capacity\u003c\/td\u003e\n        \u003ctd\u003e10 million units\u003c\/td\u003e\n        \u003ctd\u003eAnnual production capacity of vaccines and diagnostic reagents\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Investment\u003c\/td\u003e\n        \u003ctd\u003e¥150 million ($22 million)\u003c\/td\u003e\n        \u003ctd\u003e15% of annual revenue dedicated to research\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eQuality Control Tests\u003c\/td\u003e\n        \u003ctd\u003e2000 tests\u003c\/td\u003e\n        \u003ctd\u003eAnnual quality tests performed to ensure product safety\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eQuality Pass Rate\u003c\/td\u003e\n        \u003ctd\u003e99.5%\u003c\/td\u003e\n        \u003ctd\u003eRate of products passing quality assurance checks\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eOverall, these key activities enable Shenzhen Weiguang Biological Products Co., Ltd. to effectively deliver high-quality biological products to its customers, aligning with its mission of enhancing public health through innovative solutions.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen Weiguang Biological Products Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eThe key resources of Shenzhen Weiguang Biological Products Co., Ltd. play a crucial role in its ability to innovate and compete in the biotechnology industry. Below is a detailed overview of the essential assets the company relies on to create and deliver value.\u003c\/p\u003e\n\n\u003ch3\u003eAdvanced Laboratory Facilities\u003c\/h3\u003e\n\u003cp\u003eShenzhen Weiguang invests significantly in state-of-the-art laboratory facilities to support its research and development initiatives. The company operates multiple laboratories equipped with cutting-edge technology.\u003c\/p\u003e\n\u003cp\u003eAs of 2023, the company reportedly has over \u003cstrong\u003e5,000 square meters\u003c\/strong\u003e of laboratory space dedicated to various biotechnological applications. These facilities are designed to facilitate high-throughput screening and advanced genetic sequencing.\u003c\/p\u003e\n\u003cp\u003eIn 2022, the company allocated approximately \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e (~USD 22 million) for upgrading its laboratory infrastructure, showcasing its commitment to maintaining cutting-edge capabilities.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Biotechnologists\u003c\/h3\u003e\n\u003cp\u003eThe human capital at Shenzhen Weiguang is another critical resource. The company has assembled a team of highly skilled biotechnologists, contributing to its research excellence and product development.\u003c\/p\u003e\n\u003cp\u003eAs of the latest reports, the company employs over \u003cstrong\u003e200 biotechnologists\u003c\/strong\u003e and scientists, many of whom hold advanced degrees (Masters or PhDs) in relevant fields. This diverse team enhances innovation, with approximately \u003cstrong\u003e30%\u003c\/strong\u003e of the staff having over \u003cstrong\u003e10 years\u003c\/strong\u003e of industry experience.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property Rights\u003c\/h3\u003e\n\u003cp\u003eShenzhen Weiguang's robust portfolio of intellectual property rights underpins its competitive advantage in the market. The company holds numerous patents covering various biotechnological processes and products.\u003c\/p\u003e\n\u003cp\u003eAs of 2023, it possesses over \u003cstrong\u003e50 patents\u003c\/strong\u003e, including proprietary technologies for drug delivery systems and diagnostic tools. The estimated market value of these patents is around \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e (~USD 43 million), highlighting their significance in safeguarding the company’s innovations and generating revenue through licensing agreements.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eKey Resource\u003c\/th\u003e\n    \u003cth\u003eDescription\u003c\/th\u003e\n    \u003cth\u003eValue\/Amount\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLaboratory Facilities\u003c\/td\u003e\n    \u003ctd\u003eHigh-tech laboratories for R\u0026amp;D\u003c\/td\u003e\n    \u003ctd\u003e5,000 square meters\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInfrastructure Investment\u003c\/td\u003e\n    \u003ctd\u003eFunds allocated for lab upgrades\u003c\/td\u003e\n    \u003ctd\u003eRMB 150 million (~USD 22 million)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSkilled Workforce\u003c\/td\u003e\n    \u003ctd\u003eNumber of biotechnologists and scientists\u003c\/td\u003e\n    \u003ctd\u003e200\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePatent Portfolio\u003c\/td\u003e\n    \u003ctd\u003eTotal patents held\u003c\/td\u003e\n    \u003ctd\u003e50\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarket Value of Patents\u003c\/td\u003e\n    \u003ctd\u003eEstimated intellectual property value\u003c\/td\u003e\n    \u003ctd\u003eRMB 300 million (~USD 43 million)\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen Weiguang Biological Products Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003eShenzhen Weiguang Biological Products Co., Ltd. stands out in the biotechnology sector with its robust value propositions designed to cater to specific customer needs.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality biological products\u003c\/h3\u003e\n\u003cp\u003eWeiguang focuses on the production of high-quality biological products, including a range of biopharmaceuticals and reagents. The company reports that its products have an average purity level of over \u003cstrong\u003e95%\u003c\/strong\u003e, ensuring optimal efficacy for end-users. In 2022, the revenue from its biological products segment reached approximately \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e, highlighting the significance of quality in driving sales.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative solutions for health issues\u003c\/h3\u003e\n\u003cp\u003eInnovation is a cornerstone of Weiguang's offerings. The company allocates over \u003cstrong\u003e10%\u003c\/strong\u003e of its annual revenue towards research and development, which amounted to around \u003cstrong\u003eRMB 50 million\u003c\/strong\u003e in 2022. This investment has facilitated the introduction of over \u003cstrong\u003e20 new products\u003c\/strong\u003e in the last two years, addressing various health issues, including immunological disorders and infectious diseases. For instance, their latest product, a novel recombinant protein therapeutic, has shown a clinical efficacy rate exceeding \u003cstrong\u003e85%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eCompliance with international standards\u003c\/h3\u003e\n\u003cp\u003eShenzhen Weiguang ensures that all its products comply with international manufacturing standards, such as ISO 9001 and ISO 13485. As of 2023, approximately \u003cstrong\u003e80%\u003c\/strong\u003e of Weiguang's products are certified for use in markets such as the EU and the US. This compliance not only enhances product credibility but also opens up significant market opportunities, contributing to an export growth rate of \u003cstrong\u003e15%\u003c\/strong\u003e year-on-year.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eValue Proposition\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eImpact on Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHigh-quality biological products\u003c\/td\u003e\n        \u003ctd\u003eAverage purity level over 95%\u003c\/td\u003e\n        \u003ctd\u003eRMB 500 million in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eInnovative solutions for health issues\u003c\/td\u003e\n        \u003ctd\u003eOver 20 new products launched; 10% of revenue in R\u0026amp;D\u003c\/td\u003e\n        \u003ctd\u003eRMB 50 million investment in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCompliance with international standards\u003c\/td\u003e\n        \u003ctd\u003e80% products certified for EU and US markets\u003c\/td\u003e\n        \u003ctd\u003e15% year-on-year export growth\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen Weiguang Biological Products Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eShenzhen Weiguang Biological Products Co., Ltd. employs various strategies to foster customer relationships, crucial for enhancing customer acquisition, retention, and overall sales performance.\u003c\/p\u003e\n\n\u003ch3\u003ePersonalized Customer Service\u003c\/h3\u003e\n\u003cp\u003eShenzhen Weiguang offers tailored customer service experiences, allowing clients to interact directly with trained representatives. In 2022, the company reported an increase in customer satisfaction ratings to \u003cstrong\u003e87%\u003c\/strong\u003e, attributed to personalized service and dedicated support teams. The organization employs over \u003cstrong\u003e150 customer service representatives\u003c\/strong\u003e, emphasizing its commitment to addressing specific client needs.\u003c\/p\u003e\n\n\u003ch3\u003eRegular Updates on Products\u003c\/h3\u003e\n\u003cp\u003eThe company maintains proactive communication with its customers through regular product updates. In the last quarter of 2022, Shenzhen Weiguang launched \u003cstrong\u003e12 new products\u003c\/strong\u003e, with client feedback indicating a \u003cstrong\u003e75%\u003c\/strong\u003e approval rating on product innovations. The company utilizes a subscription model for product updates, which has led to a \u003cstrong\u003e30% increase\u003c\/strong\u003e in customer engagement on digital platforms.\u003c\/p\u003e\n\n\u003ch3\u003eTraining and Support\u003c\/h3\u003e\n\u003cp\u003eShenzhen Weiguang provides comprehensive training and support for its products. In the fiscal year 2022, the company conducted over \u003cstrong\u003e100 training sessions\u003c\/strong\u003e, reaching more than \u003cstrong\u003e2,000 clients\u003c\/strong\u003e. The training program has resulted in a \u003cstrong\u003e60%\u003c\/strong\u003e reduction in product-related inquiries, demonstrating its effectiveness. Financially, this program has contributed to an engagement rate that correlates with a \u003cstrong\u003e15% increase\u003c\/strong\u003e in repeat purchases within the same year.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eCustomer Satisfaction Rating\u003c\/th\u003e\n        \u003cth\u003eNew Products Launched\u003c\/th\u003e\n        \u003cth\u003eTraining Sessions Conducted\u003c\/th\u003e\n        \u003cth\u003eClients Reached\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2020\u003c\/td\u003e\n        \u003ctd\u003e80%\u003c\/td\u003e\n        \u003ctd\u003e8\u003c\/td\u003e\n        \u003ctd\u003e50\u003c\/td\u003e\n        \u003ctd\u003e1,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003e83%\u003c\/td\u003e\n        \u003ctd\u003e10\u003c\/td\u003e\n        \u003ctd\u003e75\u003c\/td\u003e\n        \u003ctd\u003e1,500\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003e87%\u003c\/td\u003e\n        \u003ctd\u003e12\u003c\/td\u003e\n        \u003ctd\u003e100\u003c\/td\u003e\n        \u003ctd\u003e2,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThese metrics highlight the effectiveness of Shenzhen Weiguang's customer relationship strategies, reflecting the company's focus on personalized service, regular communication, and robust support systems, all of which are integral to its business model.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen Weiguang Biological Products Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eShenzhen Weiguang Biological Products Co., Ltd. utilizes multiple channels to effectively communicate and deliver its value proposition to customers. These channels are crucial for reaching health institutions and ensuring that products are accessible to end-users. The following details highlight the key channels employed by the company.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales to Health Institutions\u003c\/h3\u003e\n\u003cp\u003eShenzhen Weiguang focuses on direct sales to hospitals and clinics, which represented approximately \u003cstrong\u003e60%\u003c\/strong\u003e of its annual revenue in 2022. This channel allows the company to build long-term relationships with healthcare providers and understand their specific needs. For instance, in 2022, direct sales generated revenues of around \u003cstrong\u003e¥240 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eDistributors in Pharmaceutical Networks\u003c\/h3\u003e\n\u003cp\u003eThe company has established a network of distributors across various pharmaceutical sectors. This channel accounted for about \u003cstrong\u003e30%\u003c\/strong\u003e of the overall revenue. The partnership with over \u003cstrong\u003e150\u003c\/strong\u003e distributors facilitates wider reach and accessibility of products in smaller health facilities and pharmacies. In 2022, sales through this channel yielded approximately \u003cstrong\u003e¥120 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platform for Orders\u003c\/h3\u003e\n\u003cp\u003eIn recent years, Shenzhen Weiguang has invested in digital infrastructure, enabling customers to place orders through an online platform. This channel has been growing rapidly, accounting for nearly \u003cstrong\u003e10%\u003c\/strong\u003e of total revenues in 2022. The online sales channel reported revenue of around \u003cstrong\u003e¥40 million\u003c\/strong\u003e, reflecting a year-on-year growth rate of \u003cstrong\u003e25%\u003c\/strong\u003e. This indicates a rising trend in e-commerce among healthcare providers.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eChannel Type\u003c\/th\u003e\n        \u003cth\u003eRevenue (2022)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate (Year-on-Year)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Sales to Health Institutions\u003c\/td\u003e\n        \u003ctd\u003e¥240 million\u003c\/td\u003e\n        \u003ctd\u003e60%\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistributors in Pharmaceutical Networks\u003c\/td\u003e\n        \u003ctd\u003e¥120 million\u003c\/td\u003e\n        \u003ctd\u003e30%\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Platform for Orders\u003c\/td\u003e\n        \u003ctd\u003e¥40 million\u003c\/td\u003e\n        \u003ctd\u003e10%\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn conclusion, Shenzhen Weiguang Biological Products Co., Ltd. employs a multi-faceted channel strategy that encompasses direct sales, distribution partnerships, and a robust online ordering system. This diversification allows the company to cater to a broader customer base while adapting to the evolving landscape of the healthcare market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen Weiguang Biological Products Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eShenzhen Weiguang Biological Products Co., Ltd. targets several key customer segments that drive its operational efficiency and revenue growth. Below are the primary customer groups:\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eShenzhen Weiguang serves a diverse range of hospitals and clinics, which are critical to its business model. In 2022, the total number of hospitals in China reached approximately \u003cstrong\u003e36,000\u003c\/strong\u003e, with around \u003cstrong\u003e2,800\u003c\/strong\u003e of those being private hospitals. The demand for biological products within hospitals is driven by the increasing need for diagnostics and treatment solutions.\u003c\/p\u003e\n\u003cp\u003eAccording to industry reports, the healthcare market is projected to grow at a compound annual growth rate (CAGR) of \u003cstrong\u003e12%\u003c\/strong\u003e from 2023 to 2028, indicating a robust opportunity for product sales.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Companies\u003c\/h3\u003e\n\u003cp\u003ePharmaceutical companies comprise another significant customer segment. In 2021, the total revenue of the pharmaceutical industry in China reached approximately \u003cstrong\u003eUSD 165 billion\u003c\/strong\u003e, with a growth expectancy aligned with global healthcare trends. The demand for high-quality biological reagents and diagnostic tools from these companies facilitates partnerships and collaborations.\u003c\/p\u003e\n\u003cp\u003eShenzhen Weiguang supplies various products to at least \u003cstrong\u003e100\u003c\/strong\u003e pharmaceutical firms, enhancing their research and development efficiency. The pharmaceutical sector is expected to expand at a CAGR of \u003cstrong\u003e10%\u003c\/strong\u003e, representing substantial future business potential.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Laboratories\u003c\/h3\u003e\n\u003cp\u003eResearch laboratories, both academic and corporate, are integral to Shenzhen Weiguang's customer segments. The investment in research and development has significantly increased globally. For instance, in 2022, global R\u0026amp;D spending in life sciences exceeded \u003cstrong\u003eUSD 200 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn China alone, \u003cstrong\u003eover 1,200\u003c\/strong\u003e research institutions were reported, many of which are dedicated to biopharmaceutical research. This segment's appetite for innovative biological products places Shenzhen Weiguang in a favorable position to meet the growing demand. As of 2023, the global market for biotechnology is projected to reach approximately \u003cstrong\u003eUSD 1 trillion\u003c\/strong\u003e by 2024, underscoring the importance of this segment.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eNumber of Entities\u003c\/th\u003e\n        \u003cth\u003eMarket Size (2022)\u003c\/th\u003e\n        \u003cth\u003eProjected Growth Rate (CAGR)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n        \u003ctd\u003e36,000\u003c\/td\u003e\n        \u003ctd\u003eUSD 165 billion\u003c\/td\u003e\n        \u003ctd\u003e12%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Companies\u003c\/td\u003e\n        \u003ctd\u003e100+\u003c\/td\u003e\n        \u003ctd\u003eUSD 165 billion\u003c\/td\u003e\n        \u003ctd\u003e10%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Laboratories\u003c\/td\u003e\n        \u003ctd\u003e1,200+\u003c\/td\u003e\n        \u003ctd\u003eUSD 200 billion\u003c\/td\u003e\n        \u003ctd\u003e9%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThe customer segments of Shenzhen Weiguang Biological Products Co., Ltd. not only highlight the company's diverse market presence but also reflect on the robust growth potential amid evolving healthcare needs and advancements in biotechnology.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen Weiguang Biological Products Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003cp\u003eShenzhen Weiguang Biological Products Co., Ltd. allocates a significant portion of its budget towards research and development to enhance its product offerings and maintain competitive advantage. In the fiscal year 2022, R\u0026amp;D expenses totaled approximately \u003cstrong\u003e¥120 million\u003c\/strong\u003e, constituting about \u003cstrong\u003e15%\u003c\/strong\u003e of the company's total revenue.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing costs for Shenzhen Weiguang are critical to its operational efficiency. For 2022, it reported total manufacturing expenses of around \u003cstrong\u003e¥600 million\u003c\/strong\u003e. This figure encompasses various components such as raw materials, labor, and overhead. The cost breakdown is represented in the following table:\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Component\u003c\/th\u003e\n        \u003cth\u003eAmount (¥ million)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRaw Materials\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e350\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLabor\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e150\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOverhead\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMaintenance and Utilities\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e50\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRegulatory Compliance Costs\u003c\/h3\u003e\n\u003cp\u003eCompliance with regulatory standards is essential in the biotechnology sector. Shenzhen Weiguang incurred approximately \u003cstrong\u003e¥40 million\u003c\/strong\u003e in regulatory compliance costs for the year ending 2022. This includes expenses for audits, certifications, and quality assurance processes to meet local and international regulations.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen Weiguang Biological Products Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eShenzhen Weiguang Biological Products Co., Ltd. generates its revenue through multiple streams, reflecting its diverse business activities and market engagement. The key revenue streams include product sales, licensing of technology, and research grants and funding.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eThe primary revenue source for Shenzhen Weiguang is from the direct sales of biological products. In 2022, the company's product sales accounted for approximately\u003cstrong\u003e 75% \u003c\/strong\u003e of its total revenue. The product range includes various biopharmaceuticals and diagnostic products.\u003c\/p\u003e\n\u003cp\u003eIn 2022, total revenue from product sales was reported at \u003cstrong\u003eCNY 1.2 billion\u003c\/strong\u003e, a growth of \u003cstrong\u003e15%\u003c\/strong\u003e compared to the previous year.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing of Technology\u003c\/h3\u003e\n\u003cp\u003eShenzhen Weiguang also earns revenue through the licensing of its proprietary technology to other firms. In the fiscal year 2022, the income generated from licensing agreements reached \u003cstrong\u003eCNY 150 million\u003c\/strong\u003e, representing around \u003cstrong\u003e10% \u003c\/strong\u003e of total revenue.\u003c\/p\u003e\n\u003cp\u003eDetails of the licensing agreements include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eExclusive rights granted to overseas manufacturers\u003c\/li\u003e\n  \u003cli\u003ePartnerships with local biotech firms for co-development projects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese licensing agreements allow the company to leverage its research and development investments while expanding its market reach.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Grants and Funding\u003c\/h3\u003e\n\u003cp\u003eResearch grants and funding form another vital revenue source, contributing approximately \u003cstrong\u003e15%\u003c\/strong\u003e to the company's revenue stream. In 2022, total funding and grants amounted to \u003cstrong\u003eCNY 250 million\u003c\/strong\u003e. These grants are primarily sourced from governmental and academic institutions aimed at promoting biotechnology research.\u003c\/p\u003e\n\u003cp\u003eThe distribution of grants and funding was as follows:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eSource\u003c\/th\u003e\n    \u003cth\u003eAmount (CNY Million)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Funding\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGovernment Grants\u003c\/td\u003e\n    \u003ctd\u003e150\u003c\/td\u003e\n    \u003ctd\u003e60%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAcademic Collaborations\u003c\/td\u003e\n    \u003ctd\u003e70\u003c\/td\u003e\n    \u003ctd\u003e28%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eIndustry Partnerships\u003c\/td\u003e\n    \u003ctd\u003e30\u003c\/td\u003e\n    \u003ctd\u003e12%\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eThese funds support ongoing projects in drug development and biological research, reinforcing the company's innovations in the biotechnology sector.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45662158880917,"sku":"002880sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/002880sz-business-model-canvas.png?v=1739112003","url":"https:\/\/dcf-model.com\/fr\/products\/002880sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}